Levormeloxifene - a non-hormonal woman-centric oral contraceptive under development: a comprehensive review
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20253126Keywords:
Benzopyran SERM, Health effects, Levormeloxifene, Pharmaceutical properties, Preparation, Pharmacokinetics, Pharmacodynamics, Structure, SafetyAbstract
The drugs controller general of India (DCGI) has granted permission to Cipla Limited, an Indian pharmaceutical company, to conduct Phase-I clinical trial of levormeloxifene for development as oral contraceptive for women as joint collaboration with CSIR-Central Drug Research Institute, Lucknow, India (CSIR-CDRI). Levormeloxifene is laevorotatory enantiomer of ormeloxifene, a benzopyran Selective Estrogen Receptor Modulator (SERM). Ormeloxifene is racemic mixture in equal quantities of levo- and dextro-enantiomers (compounds having same chemical composition but mirror-image 3-dimensional structures). In rats, levormeloxifene [Minimum Effective Dose (MED): 0.15 mg/kg/day] prevented pregnancy at almost half the dose than ormeloxifene (MED: 0.25 mg/kg/day) when administered orally covering the entire pre-implantation period. Levormeloxifene is equally effective as single 1 mg/kg dose when administered within 24 hours of coitus. In accordance with its higher relative binding affinity (RBA: 15.7±3.1 percent of estradiol-17β), levormeloxifene exhibited more potent estrogenic and antiestrogenic activities than the d-ormeloxifene (RBA: 2.10±0.9) or dl-ormeloxifene (RBA: 5.24±1.45). Besides, it shows promise in prevention of increased bone turnover and destructive joint diseases, and beneficial effect on serum lipids. This is the first comprehensive review providing relevant published information on structure, pharmaceutical properties, preparation, safety, pharmacokinetics and pharmacodynamics of levormeloxifene.
Metrics
References
En.wikipedia.org. Levormeloxifene, 2023. Available at: https://en.wikipedia.org/wiki/ Levormeloxifene. Accessed 20 May 2025.
Singh MM. Centchroman, a selective estrogen receptor modulator, as contraceptive and in the management of hormone related clinical disorders. Med Res Rev. 2001;21:302-47. DOI: https://doi.org/10.1002/med.1011.abs
Singh MM. Chhaya: The nonsteroidal, nonhormonal once-a-week oral contraceptive pill. In: Advances in Medicine and Biology. Nova Science Publishers, Inc; 2020: 117-72.
CDSCO.gov.in. Recommendations of the SEC meeting to examine IND proposals, made in its 36th meeting held on 05.06.2023, 12:00 Noon at CDSCO, HQ New Delhi, through Webex (Video Conference), 2023. Available at: https://cdsco.gov.in/opencms/resources. Accessed on 20 May 2024.
CSIR-CDRI. DCGI grants Permission for Phase I Clinical Trial of Levormeloxifene, developed by CSIR-CDRI and Cipla. CSIR News, 2024. Available at http://aapkikhabar.com/local/dcgi-grants-permission-for-phase-i-clinical-trial--of/cid11902493.htm; https://csirnews.niscpr.res.in/home/article/575. Accessed on 20 May 2025.
Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001;86(2):755-60. DOI: https://doi.org/10.1210/jc.86.2.755
Holm P, Shalmi M, Korsgaard N, Guldhammer B, Skouby SO, Stender S. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscler Thromb Vasc Biol. 1997;17(10):2264-72. DOI: https://doi.org/10.1161/01.ATV.17.10.2264
Gupta S, Mukhopadhyay A, Ray S, Giri AK. Comparative antimutagenic effects of D- and L-centchroman and their comparison with tamoxifen in Salmonella assay. Mutat Res. 1999;445(1):1-8. DOI: https://doi.org/10.1016/S1383-5718(99)00148-5
Ravn P, Nielsen TF, Christiansen C. What can be learned from the levormeloxifene experience. Acta Obstet Gynaecol Scand. 2006;85(2):135-42. DOI: https://doi.org/10.1080/00016340500345691
Kamboj VP, Ray S, Anand N. Centchroman: A safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front Biosci. 2018;10:1-14. DOI: https://doi.org/10.2741/e807
Devi LT, Nomonkar R. Ormeloxifene in management of dysfunctional uterine bleeding Int J Reprod Contracept Obstet Gynecol. 2018;7(5):1885-92. DOI: https://doi.org/10.18203/2320-1770.ijrcog20181923
En.wikipedia.org. List of selective estrogen receptor modulators, 2024. Available at https://en.wikipedia.org/wiki/List_of_selective_estrogen_receptor_modulators. Accessed on 20 May 2025.
En.wikipedia.org. Benzopyran, 2024. Available at https://en.wikipedia.org/wiki/ Benzopyran. Accessed 20 May 2025.
Novo Nordisk. Crystalline levormeloxifene fumarate, 1997. Available at https://patents.google.com/patent/IL126345A/en. Accessed 3 October 2024.
MedKoo Biosciences, Inc. Levormeloxifene fumarate. 2024. Available at https://www.medkoo.com/products. Accessed 3 October 2024.
Salman M, Ray S, Kamboj VP, Anand N. Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof, 1984. United States Patent 4447622. Application No.: 304507; Filed 22 September 1981. Available at https://patentimages.storage.googleapis.com/18/cf/69/9929967bb78472/US4447622.pdf. Accessed 2 October 2024.
Skrumsagar BK, Kiehr B, Pedersen PC, Gerrits M, Watson N, Bjarnason K. Levormeloxifene: Safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective estrogen receptor modulator. Br J Clin Pharmacol. 2002;53(3):284-95. DOI: https://doi.org/10.1046/j.0306-5251.2001.01181.x
Scholar E. Levormeloxifene. In: Pharm: The Comprehensive Pharmacology. Elsevier. 2007:1-4. DOI: https://doi.org/10.1016/B978-008055232-3.62979-4
Kiehr B, Skrumsagar BK, Muller M, Pedersen PC. Pharmacokinetics of levormeloxifene in young versus elderly postmenopausal women. Clin Therap. 2001;23(1):62-71. DOI: https://doi.org/10.1016/S0149-2918(01)80030-8
Mountfield RJ, Kiehr B, John BA. Metabolism, disposition, excretion and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat. Drug Metab Disp. 2000;28(5):503-13. DOI: https://doi.org/10.1016/S0090-9556(24)15093-3
Chauhan D, Maity D, Yadav PK, Vishwakarma S, Agarwal A, Chourasia MK. Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: Simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry. Nanomed. 2024;19(12):1051-68. DOI: https://doi.org/10.2217/nnm-2024-0023
Mountfield RJ, Panduro AM, Wassmann O, Thompson M, John BA, van der Merbel N. Metabolism of levormeloxifene, a selective oestrogen receptor modulator, in the Sprague-Dawley rat, cynomolgus monkey and postmenopausal woman. Xenobiotica. 2000;30(2):201-17. DOI: https://doi.org/10.1080/004982500237785
Bain S, Shalmi M, Korsgaard N. Levormeloxifene, a nonsteroidal estrogen receptor therapeutic, prevents bone loss, reduces serum cholesterol and has differentiated uterine effects in the ovariectomized rat. Maturitas. 1997;27(1):144. DOI: https://doi.org/10.1016/S0378-5122(97)81283-2
Hotchkiss CE, Stavisky R, Nowak J, Brommage R, Lees CJ, Kaplan J. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone. 2001;29(1):7-15. DOI: https://doi.org/10.1016/S8756-3282(01)00465-3
Warming L, Christoffersen C, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Adverse effects of a SERM (Levormeloxifene): Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas. 2003;44(3):189-99. DOI: https://doi.org/10.1016/S0378-5122(02)00342-0
Bloch-Thomsen A, Silvestri S, Christiansen C, Bjarnason NH. Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: Levormeloxifene and raloxifene. Clinical Trial Climacteric. 2003;6(2):159-67. DOI: https://doi.org/10.1080/cmt.6.2.159.167
Nordisk N. Novo Nordisk ends levormeloxifene trials, cites safety concerns, 1998. Available at: https://www.pharmaceuticalonline.com/doc/novo-nordisk-ends-levormeloxifene-trials-cite-0001. Accessed on 2 October 2024.
Christgau S, Tank SLB, Cloos PAC, Mouritzen U, Christiansen C, Delaiss J, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen receptor modulator SERM. Menopause. 2004;11(5):508-18. DOI: https://doi.org/10.1097/01.WCB.0000121484.18437.98
Garnero P. Biochemical markers of osteoarthritis. In: Osteoarthritis. Available at: https://www.sciencedirect.com/topics/neuroscience/ levormeloxifene. Accessed on 3 October 2024.
Ushiyama T, Ueyama H, Inoue K, Ohkubo I, Hukuda S. Expression of genes for estrogen receptors α and β in human articular chondrocytes. Osteoarth Cartil. 1999;7(6):560-6. DOI: https://doi.org/10.1053/joca.1999.0260
Spector TD, Nandra D, Hart DJ, Doyle DV. Is hormone replacement therapy protective for hand and knee osteoarthritis in women. The Chingford Study. Ann Rheum Dis. 1997;56:432-4. DOI: https://doi.org/10.1136/ard.56.7.432
Cirillo DJ, Wallace RB, Wu LL, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum. 2006;54(10):3194-204. DOI: https://doi.org/10.1002/art.22138
Surin WR, Bhalla H, Kuriakose GC, Singh MM. Assessment of raloxifene, estradiol-17β, dl-ormeloxifene and levormeloxifene on thrombin activity. Basic Clin Physiol Pharmacol. 2014;27:1-8. DOI: https://doi.org/10.1515/jbcpp-2013-0056
Salman S, Ray S, Anand N, Agarwal AK, Singh MM, Setty BS, et al. Studies in antifertility agents 50. The stereoselective binding of d-, l-centchroman to estrogen receptor and their antifertility activity. J Med Chem. 1986;29:1801-3. DOI: https://doi.org/10.1021/jm00159a044
Singh MM. Personal communication and CSIR-CDRI Annual Report 2000-2001.
Ray S, Tandon A, Dwivedy I, Wilson SR, O'Neil JP, Katzenellenbogen JA. An x-ray crystallographic study of the nonsteroidal contraceptive agent centchroman. J Med Chem. 1994;37:696-700. DOI: https://doi.org/10.1021/jm00031a020
Korsgaard N, Greenspan D, Kurman R, Bain S. Levormeloxifene, a nonsteroidal partial estrogen receptor therapeutic, exerts a non-proliferative action on uterine tissues in the ovariectomized rat. Maturitas1997;27(1):145. DOI: https://doi.org/10.1016/S0378-5122(97)81287-X
Goodrich JA, Clarkson TB, Cline JM, Jenkins AJ, Del Signore MJ. Value of the micropig model of menopause in the assessment of benefits and risks of postmenopausal therapies for the cardiovascular and reproductive tissues. Fertil Steril. 2003;79(1):779-88. DOI: https://doi.org/10.1016/S0015-0282(02)04826-4
Vardy MD, Lindsay R, Scotti RJ, Mikhail M, Richart RM, Nieves J, et al. Short-term urogenital effects of raloxifene, tamoxifen and estrogen. Am J Obstet Gynecol. 2003;189(1):81-8. DOI: https://doi.org/10.1067/mob.2003.374
Hendrix SL, McNeeley SG. Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann NY Acad Sci. 2001;949:243-50. DOI: https://doi.org/10.1111/j.1749-6632.2001.tb04028.x
Malhotra KP, Sherpa M, Bhatia A. Centchroman: Is unsupervised long-term use Warranted: Case report. Eur J Contracept Reprod Health Care. 2011;16:403-6. DOI: https://doi.org/10.3109/13625187.2011.595851
Padmaja A, Vemulapalli P, Devi KJP. Rare case of endometrial hyperplasia following unsupervised prolonged use of ormeloxifene. IOSR J Dent Med Sci. 2013;5:55-7. DOI: https://doi.org/10.9790/0853-0545557
Agarwal R, Radhakrishnan G, Radhika AG, Grover A. Abnormal uterine bleed - An adverse event of long-term centchroman use. Indian J Mater Child Health. 2014;16:1-7.
Ansari MK, Sharma PP, Khan S. Pelvic Organ Prolapse in perimenopausal and menopausal women. The J Obstet Gynecol India. 2022;72(3):250-7. DOI: https://doi.org/10.1007/s13224-021-01524-8
Wang B, Chen Y, Zhu X, Wang T, Li M, Huang Y, et al. Global burden and trends of pelvic organ prolapse associated with aging women: An observational trend study from 1990 to 2019. Front Public Health. 2022;10:975829. DOI: https://doi.org/10.3389/fpubh.2022.975829
Hsu Y, DeLancey JO. Functional anatomy and pathophysiology of pelvic organ prolapse. In: Female Urology. WB Saunders. 2008;53:542-55. DOI: https://doi.org/10.1016/B978-1-4160-2339-5.50102-6
Takacs P, Yavagal S, Zhang Y, Candiotti K, Medina CA. Levormeloxifene inhibits vaginal tropoelastin and transforming growth factor beta 1 production. J Smooth Muscle Res. 2011;47(1):11-9. DOI: https://doi.org/10.1540/jsmr.47.11
Hopkinsmedicine.org. Urinary incontinence in women: What you need to know. 2024. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/ urinary-incontinence/urinary-incontinence-in. Accessed on 15 October 2024.
Ewies EE, Elshafie M, Li J, Stanley A, Thompson J, Styles J, et al. Changes in transcription profile and cytoskeleton morphology in pelvic ligament fibroblasts in response to stretch: The effects of estradiol and levormeloxifene. Mol Hum Reprod. 2008;14:127-35. DOI: https://doi.org/10.1093/molehr/gam090
Banie L, Lin G, Ning H, Wang G, Lue TF, Lin C-S. Effects of estrogen, raloxifene and levormeloxifene on alpha1A-adrenergic receptor expression. J Urol. 2008;180(5):2241-6. DOI: https://doi.org/10.1016/j.juro.2008.07.020
Ning N, Lin G, Lue TF, Lin C. Effects of estrogen, raloxifene and levormeloxifene on the expression of rho kinase signaling molecules in urethral smooth muscle cells. Urology. 2010;76(6):1516–7. DOI: https://doi.org/10.1016/j.urology.2010.07.470
Obgynkey.com. Effect of hormone replacement. and selective estrogen receptor modulators (SERMs) on the biomechanics and biochemistry of pelvic support ligaments in the cynomolgus monkey (Macaca fascicularis), 2017. Available at: https://obgynkey.com/effectof-hormone-replacement-and-selectiveestrogen-receptor-modulators-serms-on-thebiomechanics-and-biochemistry-of-pelvicsupport-ligaments-in-the-cynomolgus-monkeymacaca-fascicularis/. Accessed on 15 October 2024.
Shahryarinejad A, Gardner TR, Cline JM, Levine WN, Bunting HA, Brodman MD, et al. Effect of hormone replacement and selective estrogen receptor modulators (SERMs) on the biomechanics and biochemistry of pelvic support ligaments in the cynomolgus monkey (Macaca fascicularis). Am J Obstet Gynecol. 2010;202(5):485. DOI: https://doi.org/10.1016/j.ajog.2010.01.074
Mokrzycki ML, Mittal K, Smilen SW, Blechman AN, Porges RF, Demopolous RI. Estrogen and progesterone receptors in the uterosacral ligament Obstet Gynecol. 1997;90(3):402-4. DOI: https://doi.org/10.1016/S0029-7844(97)00285-8
Chen GD, Oliver RH, Leung BS, Lin LY, Yeh J. Estrogen receptor alpha and beta expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women. Fertil Steril. 1999;71(6):1099-102. DOI: https://doi.org/10.1016/S0015-0282(99)00113-2
WHO.int. Women of reproductive age (15-49 years) population (thousands), 2024. Available at https://www.who.int/data/gho/indicator-metadata-registry/imr-details/women-of-reproductive-age-(15-49-years)-population-(thousands). Accessed on 27 December 2024.
Kabra R, Allagh KP, Ali M, Jayathilaka CA, Mwinga K, Kiarie J. Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill. BMJ Open 2019;4:30373. DOI: https://doi.org/10.1136/bmjopen-2019-030373
Mittal S, Sehgal R, Jindal VI, Sikka P, Kandpal S, Maiti L, et al. Single dose levonorgestrel and two regimens of centchroman for emergency contraception. J Turk-Ger Gynecol Assoc 2008;9:132-7.
Kim CM, Jeon MJ, Chung DJ, Kim SK, Kim JW, Bai SW. Risk factors for pelvic organ prolapse. Int J Gynaecol Obstet. 2007;98(3):248-51. DOI: https://doi.org/10.1016/j.ijgo.2007.02.019
Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Obstet Gynecol. 1999;94(1):66-70. DOI: https://doi.org/10.1097/00006250-199907000-00013
Downloads
Published
How to Cite
Issue
Section
